To the Editor,
Gastrointestinal angiodysplasia (GIA) is the most common digestive tract vascular malformation, often causing recurrent gastrointestinal bleeding. Despite association with certain hereditary diseases [ 1 , 2 , 3 ], most GIAs are acquired, associated with aortic stenosis, hemodialysis, malignancies, or liver cirrhosis or idiopathic, and they appear among the elderly (>60 years) [ 4 ]. Advances in endoscopy brought about management improvements, but due to numerous lesions disseminated over the digestive tract, treatment of GIA remains a clinical challenge. Novel studies suggested that the use of thalidomide might be beneficial in these patients due to its antiangiogenic properties [ 5 , 6 ]. Thalidomide and its modern analogues currently represent a backbone treatment of another disease: multiple myeloma (MM) [ 7 ]. Here we would like to present a case of successful MM and GIA treatment with thalidomide.
Our male patient, born in 1947 and suffering from arterial hypertension, benign prostate hyperplasia, and chronic obstructive pulmonary disease, was diagnosed with symptomatic iron deficiency anemia in 2012. He underwent an extensive gastroenterological workup, which revealed multiple small intestine GIAs causing recurrent bleeding. Several attempts at endoscopic argon-plasma coagulation in the following years were not able to control the disease and the patient required regular blood transfusions (every 3-4 weeks) and parenteral iron supplementation. The patient was referred to a hematologist in 2016 for further assessment. Bleeding disorders were excluded ( Table 1 ), but advanced immunoglobulin G kappa MM was found (ISS 1, with 20%-25% clonal plasma cells in the bone marrow and multiple osteolytic lesions), with no signs of bone marrow or gastrointestinal amyloidosis. Treatment with cyclophosphamide (500 mg/week), thalidomide (100 mg/day), and dexamethasone (40 mg/week) together with monthly zoledronate was initiated in March 2016. Cyclophosphamide was discontinued after 3 applications due to development of paroxysmal atrial fibrillation, requiring thromboprophylaxis with enoxaparin. Six months after treatment initiation the patient achieved a very good partial remission (vgPR) of MM. Owing to age, comorbidities, and the patient’s preferences, he was considered transplant-ineligible and so thalidomide (100 mg/day) and dexamethasone (20 mg/week) were continued. The patient has had no apparent bleeding since March 2016, he has been transfusion-free since October 2016, and he received the last parenteral iron supplementation in October 2017, so GIA endoscopy was not repeated. MM evaluations revealed continuous vgPR after 22 months of treatment; the patient is asymptomatic, suffers no side effects, and continues with thalidomide maintenance ( Table 1 ).
The efficacy of thalidomide as a first-line treatment in combination regimens and as maintenance therapy for MM is well established [ 8 ]. Despite the irrefutable success of some novel therapeutic agents, such as proteasome inhibitors and next-generation immunomodulatory drugs, thalidomide still represents a valid treatment choice, especially in countries with limited healthcare resources. Thalidomide has an emerging role in GIA treatment, with shown efficacy in a small randomized trial [ 5 ] and multiple case reports (nicely reviewed by Bauditz [ 6 ]). Certain patients, especially those with several susceptible conditions as in the case presented here, seem to achieve utmost clinical benefit and improvement in quality of life. The optimal dosage of thalidomide in GIAs is currently not defined, and the side-effect profile might limit its long-term use for disease control. Nevertheless, its efficacy and side-effect manageability make further research worthwhile.
Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
References
1 Makris M Federici AB Mannucci PM Bolton-Maggs PH Yee TT Abshire T Berntorp E The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease Haemophilia 2015 21 338 342 25381842 10.1111/hae.12571
2 Duarte BKL de Souza SM Costa-Lima C Medina SS Ozelo MC Thalidomide for the treatment of gastrointestinal bleeding due to angiodysplasia in a patient with Glanzmann’s thrombasthenia Hematol Rep 2017 9 6961 28670433 10.4081/hr.2017.6961 PMC5477473
3 Alam MA Sami S Babu S Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide BMJ Case Rep 2011 2011. 10.1136/bcr.08.2011.4585 PMC3214210 22674103
4 Becq A Rahmi G Perrod G Cellier C Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management Gastrointest Endosc 2017 86 792 806 28554655 10.1016/j.gie.2017.05.018
5 Ge ZZ Chen HM Gao YJ Liu WZ Xu CH Tan HH Chen HY Wei W Fang JY Xiao SD Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation Gastroenterology 2011 141 1629 1637 21784047 10.1053/j.gastro.2011.07.018
6 Bauditz J Effective treatment of gastrointestinal bleeding with thalidomide - chances and limitations World J Gastroenterol 2016 22 3158 3164 27003992 10.3748/wjg.v22.i11.3158 PMC4789990
7 Kumar SK Vij R Noga SJ Berg D Brent L Dollar L Chari A Treating multiple myeloma patients with oral therapies Clin Lymphoma Myeloma Leuk 2017 17 243 251 28347676 10.1016/j.clml.2017.02.024
8 Aguiar PM de Mendonça Lima T Colleoni GWB Storpirtis S Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses Crit Rev Oncol Hematol 2017 113 195 212 28427509 10.1016/j.critrevonc.2017.03.014